05-19-06

EXPRESS MAIL NO. EV 822350288 US

Date Mailed: June 15, 2006



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Stefan HECKL, et al.

Application Serial No.: 10/536,685

Filed: May 27, 2005

For: PEPTIDE CONJUGATE USEFUL

FOR CELL NUCLEUS

MOLECULAR IMAGING AND

TUMOR THERAPY

Group Art Unit: Not Yet Assigned

Examiner: Not Yet Assigned

Attorney's Docket No.:

03528.0147.PCUS00

Confirmation No.: 4627

RESPONSE TO NOTIFICATION OF DEFECTIVE RESPONSE

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Sir:

Transmitted herewith are the following:

- 1. Copy of Notification to Comply (mailed 6/13/2006)
- 2. Statement Regarding Sequence Submission (2 pgs.);
- 3. Paper Copy of Sequence Listing (5 pgs.);
- 4. Disk Containing Sequence Listing;
- 5. Return Receipt Postcard.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, including fees under §1.17; or credit any overpayment, to our Deposit Account No. <u>08-3038</u> referencing Attorney Docket No. 03528.0147.PCUS00.

Respectfully submitted,

Date: June 15, 2006

Elisabeth Evertsz (Reg. No. 50,304) Viola T. Kung (Reg. No. 41,131)

HOWREY LLP 2941 Fairview Park Drive, Box 7 Falls Church, VA 22042

Fax: (650) 798-3600 Tel. (650) 798-3570



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE UNITED STATES DEPARTMENT OF COMME Upited States Patent and Trademark Office Address COMMESIONER FOR PATENTS PO Box 1430 Alexandria, Vagals 12313-1450

U.S. APPLICATION NUMBER NO.

FIRST NAMED APPLICANT Riefan Heckl

ATTY. DOCKET NO.

10/536,685

03528.0147. PUS00

INTERNATIONAL APPLICATION NO.

27194

PCT/EP03/13413 PRIORITY DATE

HOWREY LLP C/O IP DOCKETING DEPARTMENT 2941 FAIRVIEW PARK DRIVE, SUITE 200 FALLS CHURCH, VA 22042-2924

I.A. FILING DATE 11/28/2003

11/29/2002

CONFIRMATION NO. 4627 371 FORMALITIES LETTER

OC000000019238873*

Date Mailed: 06/13/2006

NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

JUN 15 2006

Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

 A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

A copy of this notice MUST be returned with the response.

LAMONT M HUNTER

Telephone: (703) 308-9140 EXT 201